We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Molecular Probe Lights Up Staph Infections

By LabMedica International staff writers
Posted on 17 Feb 2014
A novel chemical probe comprising a self-quenching fluorescently labeled oligonucleotide allows for the rapid, noninvasive detection of staphylococcal (staph) infections.

To more easily identify sites of staph infection investigators at the University of Iowa (Iowa City, USA) created a novel molecular probe. More...
The probe comprised a pair of deoxythymidines flanked by several 2′-O-methyl–modified nucleotides. Various chemical modifications rendered the molecule resistant to mammalian serum nucleases while leaving it susceptible to the action of staphylococcal micrococcal nuclease (MN). A fluorophore was attached to one end of the probe while a molecule that quenched the fluorescence was attached to the other. The presence of the quencher prevented emission of any fluorescent light.

The action of Staphylococcus aureus MN, an endo-exonuclease that digests single-stranded and double-stranded DNA and RNA, digested the probe and liberated the fluorophore from the suppressing effect of the quencher. As the probe was susceptible to digestion only by staph MN, the appearance of fluorescence pinpointed the site of bacterial infection.

The probe's fluorescence was activated in culture supernatants of S. aureus but not in culture supernatants of several other pathogenic bacteria. Systemic administration of this probe to mice bearing S. aureus muscle infections resulted in probe activation at the infection sites in an MN-dependent manner.

"We have come up with a new way to detect staph bacteria that takes less time than current diagnostic approaches," said senior author Dr. James McNamara, assistant professor of internal medicine at the University of Iowa. "It builds on technology that has been around a long time, but with an important twist that allows our probe to be more specific and to last longer. If the probe gets cleaved by serum nucleases, then our probe would be lit up all over the bloodstream. But since it is split only by staph nucleases, then we can pinpoint where the staph bacteria are active."

The investigators applied for US patent to protect use of the molecule in the fall of 2012, and plan to refine the probe so it can be detected deeper in the body and with catheter infections.

A paper describing the novel probe for staph infections was published in the February 2, 2014, online edition of the journal Nature Medicine.

Related Links:

University of Iowa



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Urine Analyzer
respons® UDS100
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.